Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children. Issue 3 (3rd January 2023)

• Record Type: Journal Article
• Authors: Karron, Ruth A; Herbert, Kristi; Wanionek, Kimberli; Schmidt, Alexander C; Schaap-Nutt, Anne; Collins, Peter L; Buchholz, Ursula J
• Is Part Of: Journal of the Pediatric Infectious Diseases Society. Volume 12:Issue 3(2023)
• Page Start: 173
• Page End: 176
• Publication Date: 2023-01-03
• Subjects: live-attenuated -- parainfluenza -- vaccine; Communicable diseases in children -- Periodicals; Children -- Diseases -- Periodicals; 618.929
• DOI: 10.1093/jpids/piac137
• Languages: English
• ISSNs: 2048-7193

Abstract

Abstract: We conducted a phase I clinical trial of the live-attenuated recombinant human parainfluenza virus type 2 (HPIV2) vaccine candidate rHPIV2-15C/948L/∆1724 sequentially in adults, HPIV2-seropositive children, and HPIV2-seronegative children, the target population for vaccination. rHPIV2-15C/948L/∆1724 was appropriately restricted in replication in adults and HPIV2-seropositive children but was overattenuated for HPIV2-seronegative children.